Molecular prostate cancer pathology

Current issues and achievements

Jack A. Schalken, Anders Bergh, Aldo Bono, Christopher Foster, Mary Gospadarowicz, William B Isaacs, Mark Rubin, Fritz Schröder, Bernhard Tribukait, Taiji Tsukamotot, Peter Wiklund

Research output: Contribution to journalArticle

Abstract

Recent developments in the field of molecular techniques have provided new tools that have led to the discovery of many new promising biomarkers for prostate cancer. These biomarkers may be instrumental in the development of new tests that will have a high specificity for the diagnosis and prognosis of prostate cancer. A biomarker is defined as a molecular test that provides additional information to currently available clinical and pathological tests. Biomarkers should be reproducible (both within and between institutes) and have an impact on clinical management. For diagnostic purposes it is important that potential biomarkers are tested in terms of tissue specificity and their discrimination potential between prostate cancer, normal prostate and benign prostatic hyperplasia. The results of (multiple) biomarker-based assays may enhance the specificity of cancer detection. There is an urgent need for molecular prognostic biomarkers for predicting the biological behavior and outcome of cancer.

Original languageEnglish (US)
Pages (from-to)82-93
Number of pages12
JournalScandinavian Journal of Urology and Nephrology, Supplement
Volume39
Issue number216
DOIs
StatePublished - May 2005

Fingerprint

Prostatic Neoplasms
Biomarkers
Pathology
Organ Specificity
Prostatic Hyperplasia
Neoplasms

Keywords

  • Biomarkers
  • Diagnosis
  • Prognosis
  • Prostate cancer

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Molecular prostate cancer pathology : Current issues and achievements. / Schalken, Jack A.; Bergh, Anders; Bono, Aldo; Foster, Christopher; Gospadarowicz, Mary; Isaacs, William B; Rubin, Mark; Schröder, Fritz; Tribukait, Bernhard; Tsukamotot, Taiji; Wiklund, Peter.

In: Scandinavian Journal of Urology and Nephrology, Supplement, Vol. 39, No. 216, 05.2005, p. 82-93.

Research output: Contribution to journalArticle

Schalken, JA, Bergh, A, Bono, A, Foster, C, Gospadarowicz, M, Isaacs, WB, Rubin, M, Schröder, F, Tribukait, B, Tsukamotot, T & Wiklund, P 2005, 'Molecular prostate cancer pathology: Current issues and achievements', Scandinavian Journal of Urology and Nephrology, Supplement, vol. 39, no. 216, pp. 82-93. https://doi.org/10.1080/03008880510030950
Schalken, Jack A. ; Bergh, Anders ; Bono, Aldo ; Foster, Christopher ; Gospadarowicz, Mary ; Isaacs, William B ; Rubin, Mark ; Schröder, Fritz ; Tribukait, Bernhard ; Tsukamotot, Taiji ; Wiklund, Peter. / Molecular prostate cancer pathology : Current issues and achievements. In: Scandinavian Journal of Urology and Nephrology, Supplement. 2005 ; Vol. 39, No. 216. pp. 82-93.
@article{cc9749dc0c1944e187fd9651dcd75794,
title = "Molecular prostate cancer pathology: Current issues and achievements",
abstract = "Recent developments in the field of molecular techniques have provided new tools that have led to the discovery of many new promising biomarkers for prostate cancer. These biomarkers may be instrumental in the development of new tests that will have a high specificity for the diagnosis and prognosis of prostate cancer. A biomarker is defined as a molecular test that provides additional information to currently available clinical and pathological tests. Biomarkers should be reproducible (both within and between institutes) and have an impact on clinical management. For diagnostic purposes it is important that potential biomarkers are tested in terms of tissue specificity and their discrimination potential between prostate cancer, normal prostate and benign prostatic hyperplasia. The results of (multiple) biomarker-based assays may enhance the specificity of cancer detection. There is an urgent need for molecular prognostic biomarkers for predicting the biological behavior and outcome of cancer.",
keywords = "Biomarkers, Diagnosis, Prognosis, Prostate cancer",
author = "Schalken, {Jack A.} and Anders Bergh and Aldo Bono and Christopher Foster and Mary Gospadarowicz and Isaacs, {William B} and Mark Rubin and Fritz Schr{\"o}der and Bernhard Tribukait and Taiji Tsukamotot and Peter Wiklund",
year = "2005",
month = "5",
doi = "10.1080/03008880510030950",
language = "English (US)",
volume = "39",
pages = "82--93",
journal = "Scandinavian Journal of Urology and Nephrology, Supplement",
issn = "0300-8886",
publisher = "Taylor and Francis Ltd.",
number = "216",

}

TY - JOUR

T1 - Molecular prostate cancer pathology

T2 - Current issues and achievements

AU - Schalken, Jack A.

AU - Bergh, Anders

AU - Bono, Aldo

AU - Foster, Christopher

AU - Gospadarowicz, Mary

AU - Isaacs, William B

AU - Rubin, Mark

AU - Schröder, Fritz

AU - Tribukait, Bernhard

AU - Tsukamotot, Taiji

AU - Wiklund, Peter

PY - 2005/5

Y1 - 2005/5

N2 - Recent developments in the field of molecular techniques have provided new tools that have led to the discovery of many new promising biomarkers for prostate cancer. These biomarkers may be instrumental in the development of new tests that will have a high specificity for the diagnosis and prognosis of prostate cancer. A biomarker is defined as a molecular test that provides additional information to currently available clinical and pathological tests. Biomarkers should be reproducible (both within and between institutes) and have an impact on clinical management. For diagnostic purposes it is important that potential biomarkers are tested in terms of tissue specificity and their discrimination potential between prostate cancer, normal prostate and benign prostatic hyperplasia. The results of (multiple) biomarker-based assays may enhance the specificity of cancer detection. There is an urgent need for molecular prognostic biomarkers for predicting the biological behavior and outcome of cancer.

AB - Recent developments in the field of molecular techniques have provided new tools that have led to the discovery of many new promising biomarkers for prostate cancer. These biomarkers may be instrumental in the development of new tests that will have a high specificity for the diagnosis and prognosis of prostate cancer. A biomarker is defined as a molecular test that provides additional information to currently available clinical and pathological tests. Biomarkers should be reproducible (both within and between institutes) and have an impact on clinical management. For diagnostic purposes it is important that potential biomarkers are tested in terms of tissue specificity and their discrimination potential between prostate cancer, normal prostate and benign prostatic hyperplasia. The results of (multiple) biomarker-based assays may enhance the specificity of cancer detection. There is an urgent need for molecular prognostic biomarkers for predicting the biological behavior and outcome of cancer.

KW - Biomarkers

KW - Diagnosis

KW - Prognosis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=22144444603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144444603&partnerID=8YFLogxK

U2 - 10.1080/03008880510030950

DO - 10.1080/03008880510030950

M3 - Article

VL - 39

SP - 82

EP - 93

JO - Scandinavian Journal of Urology and Nephrology, Supplement

JF - Scandinavian Journal of Urology and Nephrology, Supplement

SN - 0300-8886

IS - 216

ER -